Biotech | February 17, 2022
Kato wins USFDA approval for studies in retinal disorder
Resolv ER may remedy leading causes of blindness in adults
Resolv ER may remedy leading causes of blindness in adults
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
It will open new frontier for south-to-south collaboration and innovation transfer
Key takeaways of recent quarter & conference call highlights
It is being developed by Pune-based Gennova Biopharmaceuticals
The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24
Subscribe To Our Newsletter & Stay Updated
